Figure 6
From: c-MET as a Potential Therapeutic Target in Ovarian Clear Cell Carcinoma
The anti-tumor effects of SU11274 were examined in OCCC patient-derived xenograft (PDX) models.
(A) Experimental outline for PDX model. (B) Tumor weight significantly decreased in the SU11274-treated group (n = 9) compared with the PBS-injected control group (n = 8). In each picture, the small piece on the left is normal kidney (no tumor transplanted), and the large one on the right is the developed PDX. (C) The SU11274-treated group showed less phospho-c-MET expression than the control group. (D) Tumor cell proliferation as assessed by Ki67 immunohistochemistry in harvested tumor tissues was significantly lower in the SU11274-treated group (n = 5). (E) TUNEL assay showed significantly higher apoptosis in the SU11274-treated group (error bar represents s.e.m., *p < 0.010).
